Journal of Surgery Concepts & Practice ›› 2018, Vol. 23 ›› Issue (03): 210-213.doi: 10.16139/j.1007-9610.2018.03.006
• Experts forum • Previous Articles Next Articles
Received:2018-01-29
Published:2020-07-25
CLC Number:
| [1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志,2010,18(3):163-166. [2] Bellentani S.The epidemiology of non-alcoholic fatty li-ver disease[J]. Liver Int,2017,37(Suppl 1):81-84. [3] Fan JG, Farrell GC.Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol,2009,50(1):204-210. [4] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132. [5] Rinella ME.Nonalcoholic fatty liver disease: a systematic review[J]. JAMA,2015,313(22):2263-2273. [6] Powell EE, Cooksley WG, Hanson R, et al.The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years[J]. Hepatology,1990,11(1):74-80. [7] Marengo A, Rosso C, Bugianesi E.Liver cancer: Connections with obesity, fatty liver, and cirrhosis[J]. Ann Rev Med,2016,67:103-117. [8] Ertle J, Dechene A, Sowa JP, et al.Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis[J]. Int J Cancer,2010, 128(10):2436-2443. [9] Dyson J, Jaques B, Chattopadyhay D, et al.Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team[J]. J Hepatol,2014,60(1):110-117. [10] Younossi ZM, Otgonsuren M, Henry L, et al.Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology,2015,62(6):1723-1730. [11] Salomao MS, Yu WM, Brown RS, et al.Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH[J]. Am J Surg Pathol,2010,34(11):1630-1636. [12] Salomao MS, Remotti H, Vaughan R, et al.The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis[J]. Hum Pathol,2012,43(5):737-746. [13] Shibahara J, Ando S, Sakamoto Y, et al.Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients[J]. Histopathology,2014,64(7):951-962. [14] Calwell SH, Lee VD, Kleiner DE, et al.NASH and cryptogenic cirrhosis: a histological analysis[J]. Ann Hepatol,2009,8(4):346-352. [15] Mittal S, Sada Y, El-Serag HB, et al.Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population[J]. Clin Gastroenterol Hepatol,2015,13(3):594-601. [16] Kikuchi L, Oliveira CP, Alvares-da-Silva MR, et al. Hepa-tocellular carcinoma management in nonalcoholic fatty liver disease patients: applicability of the BCLC staging system[J]. Am J Clin Oncol,2016,39(5):428-432. [17] Wong RJ, Aguilar M, Cheung R, et al.Nonalcoholic steatohepatitis is the second leading etiology of liver di-sease among adults awaiting liver transplantation in the United States[J]. Gastroenterology,2015,148(3):547-555. [18] Vigano L, Conci C, Cescon M, et al.Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC[J]. J Hepatol,2015,63(1):93-101. [19] Reddy SK, Steel JL, Chen HW, et al.Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver di-sease[J]. Hepatology,2012,55(6):1809-1819. [20] Piscaglia F, Svegliati-Baroni G, Barchetti A, et al.Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study[J].Hepatology,2016,63(3):827-838. [21] White DL, Kanwal F, El-Serag HB.Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review[J]. Clin Gastroenterol Hepatol,2012,10(12):1342-1359. [22] Bruix J, Sherman M.Management of hepatocellular carcinoma: an update[J]. Hepatology,2011,53(3):1020-1022. [23] Singal AG, Yopp AC, Gupta S, et al.Failure rates in the hepatocellular carcinoma surveillance process[J]. Cancer Prev Res,2012,5(9):1124-1130. [24] Gopal P, Yopp AC, Waljee AK, et al.Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis[J]. Clin Gastroenterol Hepatol,2014,12(5):870-877. [25] Kawanaka M, Tomiyama Y, Hyogo H, et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease[J]. Hepatol Res,2018-01-07[Epub ahead of print] [26] Zhang H, Gao C, Fang L, et al.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis[J]. Scand J Gastroenterol,2013,48(1):78-87. [27] Bhat M, Sonenberg N, Gores GJ.The mTOR pathway in hepatic malignancies[J]. Hepatology,2013,58(2):810-818. [28] Singh S, Singh PP, Singh AG, et al.Statins are associa-ted with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis[J]. Gastroenterology,2013,144(2):323-332. [29] Yang B, Yang HP, Ward KK, et al.Bariatric surgery and liver cancer in consortium of academic medical centers[J]. Obes Surg,2016,26(3):696-700. [30] Torres DM, Williams CD, Harrison SA.Features, diagnosis, and treatment of nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol,2012,10(8):837-858. [31] Wen CP, Lin J, Yang CY, et al.Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases[J]. J Natl Cancer Inst,2012,104(20):1599-1611. [32] Piguet AC, Saran U, Simillion C, et al.Regular exercise decreases liver tumors development in hepatocyte-speci-fic PTEN-deficient mice independently of steatosis[J]. J Hepatol,2015,62(6):1296-1303. |
| [1] | ZHANG Jixiang, XIE Zhihua, LI Wei, JIANG Xiaoqing. Classification of intrahepatic cholangiocarcinoma and hot topics in surgical treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 478-482. |
| [2] | YIN Yanjiang, LUO Zhiwen, CHEN Xiao, ZHANG Yefan, HUANG Zhen, ZHAO Hong, ZHAO Jianjun, LI Zhiyu, ZHOU Jianguo, CAI Jianqiang, BI Xinyu. Relationship between surgical margin and prognosis of patients with intrahepatic cholangiocarcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(3): 221-228. |
| [3] | CHEN Congyan, WANG Junqing, CHEN Yongjun. Gut microbiota and mechanism of liver cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(3): 256-260. |
| [4] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 93-94. |
| [5] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 95-99. |
| [6] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 100-106. |
| [7] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 107-112. |
| [8] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 113-118. |
| [9] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 119-122. |
| [10] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 123-127. |
| [11] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 128-130. |
| [12] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 131-133. |
| [13] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 134-138. |
| [14] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 139-144. |
| [15] | ZHANG Xihao, ZHANG Xinyun, CAO Manqing, ZHANG Jinliang, WANG Huaqi, ZHANG Su, FU Zhou, WANG Lu, ZHANG Ti. Both anti-angiogenesis and immunotherapy combined with interventional therapy in treatment of hepatocellular carcinoma: effect of hepatic artery infusion chemotherapy compared with hepatic artery chemoembolization [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 152-157. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
